Articles tagged "Adverse effects"

2020 American Transplant Congress
Relationship between Tacrolimus Levels and Short-Term Outcome in Korean Pediatric Patients with Liver Transplantation
H. Lim¹, H. Koh¹, S. Kim¹, S. Park¹, Y. Kang², M. Kim³, K. In¹
¹Severance Pediatric Liver Diseases Research Group, Severance Children’s Hospital, Severance Hospital, Seoul, Korea, Republic of, ²Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, , Wonju Severance Christian Hospital, Seoul, Korea, Republic of, ³Division of Transplantation Surgery, Department of General Surgery, Severance Hospital, Seoul, Korea, Republic of
*Purpose: Liver transplantation (LT) is a life-saving procedure in patients with end stage liver disease. After LT, immunosuppresive regimens are needed in order to prevent…
2020 American Transplant Congress
Long Term Ursodeoxycholic Acid Use Does Not Alter Long Term Rejection, Biliary Complication, Mortality or Hospitalization Rates after Liver Transplantation
T. Ashraf¹, V. Mendiratta², S. Gill¹, A. Abdelwahab³, D. Moonka², S. Jafri²
¹Internal Medicine, Henry Ford Hospital, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, ³Wayne State University, Detroit, MI
*Purpose: Endogenous bile acids are suspected to contribute to hepatobiliary injury after liver transplantation through direct cytotoxic effects. Ursodeoxycholic acid (UDCA) has been shown to…
2020 American Transplant Congress
Pharmacokinetics of Maribavir in Subjects with Moderate Hepatic Impairment
I. H. Song¹, K. Ilic², J. Wu³
¹Quantitative Clinical Pharmacology, Shire, a Takeda Company, Lexington, MA, ²Rare Disease TAU, Shire, a Takeda Company, Lexington, MA, ³Biostat, Shire, a Takeda Company, Lexington, MA
*Purpose: Maribavir, an investigational agent for cytomegalovirus (CMV) infection in transplant recipients, has received Breakthrough Therapy Designation. Maribavir is metabolized primarily in the liver through…
2020 American Transplant Congress
Optimal Transition for Transplant Recipients: A Model of Care in an Integrated Health Care System
S. Zheng¹, L. Pravoverov¹, A. Nazarova¹, D. Adey², N. B. Goes¹
¹The Permanente Medical Group, San Francisco, CA, ²Kidney and Transplantation Program, University of California San Francisco, San Francisco, CA
*Purpose: Transplantation is the treatment of choice for ESRD. While short-term outcomes have improved, long-term outcomes lag. Many factors may explain the long-term lag including…
2020 American Transplant Congress
Cost Utilization and the Use of Pulmonary Functions Tests in Preoperative Liver Transplant
M. LaGoy¹, A. Ermekbaeva², J. Buggs³, S. Nyce⁴, D. Patino⁴, E. Rogers³, A. Kumar¹, N. Kemmer⁵
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁴University of Tampa, Tampa, FL, ⁵Transplant Hepatology, Tampa General Hospital, Tampa, FL
*Purpose: The American Society of Anesthesia recommends abdominal transplant patients receive pre-operative pulmonary function tests (PFTs) which cost nearly $2,500. Up to 88 percent of…
2020 American Transplant Congress
Native Nephrectomy at the Time of Transplant: Risk for Adrenal Injury?
T. Salinas¹, D. Dadhania¹, J. Lee¹, M. Aull¹, S. Kapur², M. Lubetzky¹
¹Nephrology, NY Presbyterian- Weill Cornell, New York, NY, ²Surgery, NY Presbyterian- Weill Cornell, New York, NY
*Purpose: Living donor studies have demonstrated that native nephrectomy (Nx) is associated with transient but symptomatic loss of adrenal function. Although surgical complications from simultaneous…
2020 American Transplant Congress
Assessment of Sarcopenia and Obesity by Bioelectrical Impedance Analysis in Transplant and Hepatobiliary Populations
J. Konel¹, T. Kitajima², L. Arevalo¹, N. Murray¹, T. Pietrowsky², D. Venkat², H. Gonzalez², M. Samaniego², M. Abouljoud², S. Nagai²
¹Wayne State University School of Medicine, Detroit, MI, ²Henry Ford Transplant Institute, Detroit, MI
*Purpose: Sarcopenia and obesity are common among transplant and hepatobiliary patients; however, current methods of measuring these risk factors may provide an inadequate representation of…
2020 American Transplant Congress
Most Complications of Hand-Assisted Laparoscopic Living Donor Nephrectomy Occur after Initial Discharge Including Most Reoperations: A Single-Center Retrospective Study
X. Benavides, R. T. Rogers, E. Tan, M. A. Merzkani, S. Thirunavukkarasu, B. Smith, A. D. Rule, M. Prieto, J. K. Heimbach, T. Taner, G. K. Chow, P. G. Dean, M. D. Stegall
Kidney Transplant, Mayo Clinic, Rochester, MN
*Purpose: While most studies of hand-assisted laparoscopic living donor nephrectomy (HALLDN) report complications until discharge, this study examined complications up to 120 days.*Methods: We assessed…
2020 American Transplant Congress
Glucocorticoid-Induced Osteoporosis in Lung Transplant Patients
J. Clark, L. Potter
Department of Pharmacy, University of Chicago Medicine, Chicago, IL
*Purpose: Although vital for preventing rejection, glucocorticoids contribute to post-operative morbidity, including osteoporosis. The primary purpose of this study was to identify the occurrence of…
2020 American Transplant Congress
Effect of Different Strategies to Decrease Post-Operative Opioid Use Following Living Donor Nephrectomy
D. Quan¹, J. Lazo², J. Lee³, A. Barnes⁴, S. Kang⁵
¹UCSF Medical Center, San Francisco, CA, ²Pharmaceutical Services, UCSF Medical Center, San Francisco, CA, ³School of Pharmacy, University of California San Francisco, San Francisco, CA, ⁴Department of Pharmaceutical Services, UCSF Medical Center, San Francisco, CA, ⁵Transplant Surgery, UCSF Medical Center, San Francisco, CA
*Purpose: Living donor transplant programs are essential in decreasing the number of kidney wait-list candidates, however, of utmost importance should be ensuring our donors are…

« Previous Page
1
…
6
7
8
9
10
…
18
Next Page »